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Abstract
The relationship between ABO blood groups (BG) and risk of incidence in cancers including
gynecological cancers has been widely studied, showing increased incidence risk for BG A
patients. As available data are inconsistent we investigated whether BG and their anti-gly-
can antibodies (anti-A and anti-B) have prognostic values in gynecological cancers. We ret-
rospectively evaluated 974 patients with gynecological cancers in three cancer centers
(Switzerland and Australia) between 1974 and 2014 regarding the relationships between
clinico-pathological findings and the BG. Time to disease recurrence was significantly influ-
enced by BG in patients with ovarian (n = 282) and vulvar (n = 67) cancer. BG O or B
patients showed a significantly increased risk for ovarian cancer relapse compared to A,
59% and 82%, respectively (p = 0.045; HR O vs A = 1.59 (CI 1.01–2.51) and (p = 0.036; HR
A vs B = 0.55 (CI 0.32–0.96). Median time to relapse for advanced stage (n = 126) ovarian
cancer patients was 18.2 months for BG O and 32.2 for A (p = 0.031; HR O vs A = 2.07 (CI
1.07–4.02)). BG also significantly influenced relapse-free survival in patients with vulvar
cancer (p = 0.002), with BG O tending to have increased relapse risk compared to A (p =
0.089). Blood groups hence associate with recurrence in ovarian and vulvar cancer: women
with BG O seem to have a lower ovarian cancer incidence, however are more likely to
relapse earlier. The significance of the BG status as a prognostic value is evident and may
be helpful to oncologists in prognosticating disease outcome and selecting the appropriate
therapy.
Introduction
The ABO blood group (BG) in humans is the most important BG system in transfusion and
transplantation medicine. It is defined by two glycans, antigen A (GalNAcα1-3(Fucα1–2)
Galβ1) and B (Galα1-3(Fucα1–2)Galβ1) and is determined by the ABO gene that encodes the
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A and B allele, resulting in two different glycosyltransferase activities. These activities add
either N-acetylgalactosamine or galactose to the precursor H antigen to form A or B antigen,
respectively. The absence of both antigens in BG O owes to a frameshift mutation at the N-ter-
minus of the enzyme [1]. ABO BG antigens are commonly expressed on cell surface glyco-
sphingolipids or glycoproteins present on erythrocytes and on a variety of other human cells
and tissues (e.g. gastro-intestinal, bronchopulmonary, skin and urogenital epithelial cells [2]),
and also occur in various body fluids and secretions [3].
ABO BG are involved in several benign and malignant diseases [4] and the relationship
between human BG and cancer is well known [5]. Several studies have shown associations
between ABO BG and incidence and risk for various cancers [5] including ovarian cancer[5–
7] and several plausible explanations have been proposed explaining the observed associations
of ABO BG and cancer: these include inflammation, immune surveillance for malignant cells,
modified expression of ABO BG antigens on cancer cells as a consequence of altered glycosyl-
transferase activities [8], intercellular adhesion and membrane signaling [9], single nucleotide
polymorphisms and epigenetics [10].
Ovarian cancer (OC), usually diagnosed at an advanced FIGO stage, is the fifth leading
cause of cancer death for women and the most lethal gynecological cancer in women and
despite improved surgical techniques and drug regimens, overall survival has not changed sig-
nificantly for several decades [11]. In addition, currently used screening methods seem not
accurate enough: the combination of tumor marker CA125 and transvaginal ultrasound allows
measurement of triaging indices such as the Risk of Malignancy Index (RMI) and facilitates
discrimination between benign and malignant ovarian masses [12], and screening trials
(PLCO-, UKCTOCS-trials) have not shown benefit in terms of disease specific survival [13,
14].
The search for new and highly specific biomarkers for both early disease detection and dis-
ease prognosis is still needed and ongoing. We have previously shown that the level of plasma-
derived anti-glycan antibodies to P1 trisaccharide significantly discriminates between OC
patients and healthy women, suggesting P1 as an OC-associated carbohydrate antigen[15].
Interestingly, P1 carbohydrate antigen belongs to the human P BG system and shares oligosac-
charide sequences with Pk and P antigens [16]. In analogy to this and as we know that the clas-
sical blood system, with his anti-glycan antibodies, is involved in the pathogenesis of several
malignancies, we were interested in looking for survival association in gynecological cancer
liable to identify a prognostic marker.
Only a small body of data has been reported regarding associations between ABO BG and
survival [17–20] and even fewer and inconsistent data are available for gynecological cancers
in general and OC in particular [21, 22]. We therefore retrospectively evaluated and compared
the clinic-pathological findings including relapse-free survival (RFS), disease-specific survival
(DSS), and overall survival (OS) of a large gynecological cancer patient cohort (n = 974) to the
ABO BG status.
Materials and methods
Study cohort description
Clinicopathological databases between 1974 and 2014 from three gynecological cancer centers
in Switzerland (Basel, Zurich) and Australia (Sydney) were reviewed. Patients’ eligibility crite-
ria included at least a histologically confirmed gynecological cancer, a complete remission
after primary treatment, and an available BG status. Patients who deceased from causes other
than cancer or developed a second primary tumor which is different from the cancer they had
initially were censored in this study. Disease recurrence was diagnosed on a clinical basis
Blood groups as prognostic factor for gynecological cancer recurrence
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(symptoms) and/or increasing tumor marker followed by radiological confirmation. Histolog-
ical grades were defined according to the World Health Organization, and extent of disease by
FIGO stage. All patients underwent surgery with curative intent, adjuvant chemotherapy and/
or radiotherapy unless refused, as recommended by the interdisciplinary tumor conferences.
These recommendations were based on international data and guidelines and were individual-
ized depending to the patient’s co-morbidities. BG status (ABO system) of all patients was
determined serologically before their surgery. Patients were followed up every 3 months for
the first two years and then every 6 months until 5 years after completion of primary treat-
ment, and then then once yearly. In total 974 patients were analyzed, subdivided into 282 cases
of ovarian, 56 peritoneal, 23 tubal, 377 endometrial, 149 cervical, 11 vaginal, 67 vulvar, and 9
synchronous ovarian/endometrial cancers. This study was approved by the Swiss Medical Eth-
ical Committee, EKNZ 2015–436. Neither written nor oral consent was necessary for thir ret-
rospective study and data accession was anonymous.
Statistical analysis
Descriptive statistics comparing the study groups are reported as counts and percentages or as
mean and standard deviation (SD) as appropriate. Corresponding p-values were calculated
using Fisher’s exact tests (counts) and t-Tests (ordinal data). Relationships between clinic-
pathological findings, ABO BG, and outcome (RFS, DSS, and OS) were analyzed. RFS was
defined as the period from the date of diagnosis to the date of disease recurrence (as described
above). DSS was calculated from the date of diagnosis to death from disease. Deaths of
unknown cause or other than disease were censored. Kaplan-Meier analysis was used to calcu-
late the survival rate or time to event analysis (RFS, DSS, and OS) with a 95% confidence inter-
val (CI). Data for 5-year OS were also reported. The Log-rank test was used to compare the
survival curves. Additionally, Cox-Regression analysis including a center effect comparing
each blood group was performed. Analyses were not adjusted for covariates. Results (median
values) are reported with hazard ratios (HR), corresponding 95% CI’s and p-values. Reported
p-values were two-sided and p< 0.05 was considered statistically significant. The statistical
analyses were performed using R version 3.0.1.
Results
Clinico-pathological characteristics for all gynecological cancers patients
sorted by blood groups
This study includes 974 patients with various gynecological cancers. The mean age was
62.8 ± 13.7 years and the mean follow-up 4.8 ± 33.7 years. The BG distribution was 471
patients with BG A (48.4%), 94 patients with B (9.6%), 375 patients with O (38.5%), 34 patients
with AB (3.5%), and was similar to that of the general population in Europe. The cohort com-
prised ovarian (n = 282), peritoneal (n = 56), tubal (n = 23), cervical (n = 149), endometrial
(n = 377), vaginal (n = 11), and vulvar cancer (n = 67) patients. This and additional informa-
tion on the study cohort including tumor type, histology, stage, grade, residual disease, survival
status, and recurrence status regarding the BG status is summarized in Table 1.
Effect of blood group status on RFS, DSS, and OS in all gynecological
cancers patients
Time-to-event analysis was performed for all 7 gynecological cancer types. For DSS, no signifi-
cant associations to BG were found for these cancer types: ovarian (p = 0.696), peritoneal
(p = 0.28), tubal (p = 0.366), cervical (p = 0.723), endometrial (p = 0.39), vaginal (p = 0.26), and
Blood groups as prognostic factor for gynecological cancer recurrence
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Table 1. Clinico-pathological data of gynecological cancer cohort sorted by blood group.
ABO blood group
ALL O A AB B p n
Characteristic
Number of women 974 375 471 34 94
Percentage of total (%) 100.0 38.5 48.4 3.5 9.7
Cancer Center 0.038 974
Basel 708 (72.7%) 265 (70.7%) 364 (77.3%) 22 (64.7%) 57 (60.6%)
Sydney 210 (21.6%) 89 (23.7%) 83 (17.6%) 9 (26.5%) 29 (30.9%)
Zu¨rich 56 (5.75%) 21 (5.60%) 24 (5.10%) 3 (8.82%) 8 (8.51%)
Mean age (years) (±SD) 62.8 (13.7) 63.1 (13.8) 62.9 (13.5) 62.3 (12.2) 61.5 (14.5) 0.786 940
Organ 0.035 974
Cervix 149 (15.3%) 54 (14.4%) 81 (17.2%) 5 (14.7%) 9 (9.57%)
Endometrium 377 (38.7%) 156 (41.6%) 182 (38.6%) 13 (38.2%) 26 (27.7%)
Ovaries 282 (29.0%) 100 (26.7%) 138 (29.3%) 10 (29.4%) 34 (36.2%)
Ovaries & Endometrium 9 (0.92%) 2 (0.53%) 5 (1.06%) 1 (2.94%) 1 (1.06%)
Peritoneum 56 (5.75%) 22 (5.87%) 18 (3.82%) 3 (8.82%) 13 (13.8%)
Fallopian tube 23 (2.36%) 9 (2.40%) 9 (1.91%) 1 (2.94%) 4 (4.26%)
Vagina 11 (1.13%) 8 (2.13%) 3 (0.64%) 0 (0.00%) 0 (0.00%)
Vulva 67 (6.88%) 24 (6.40%) 35 (7.43%) 1 (2.94%) 7 (7.45%)
Tumour type 0.183 974
Adenocarcinoma 733 (75.3%) 286 (76.3%) 345 (73.2%) 25 (73.5%) 77 (81.9%)
Squamous cell carcinoma 193 (19.8%) 71 (18.9%) 103 (21.9%) 6 (17.6%) 13 (13.8%)
Carcinosarcoma (MMMT) 26 (2.67%) 11 (2.93%) 12 (2.55%) 1 (2.94%) 2 (2.13%)
Adenosarcoma 1 (0.10%) 1 (0.27%) 0 (0.00%) 0 (0.00%) 0 (0.00%)
Adenosquamous carcinoma 2 (0.21%) 1 (0.27%) 1 (0.21%) 0 (0.00%) 0 (0.00%)
Sarcoma 7 (0.72%) 4 (1.07%) 0 (0.00%) 2 (5.88%) 1 (1.06%)
Carcinoid 1 (0.10%) 1 (0.27%) 0 (0.00%) 0 (0.00%) 0 (0.00%)
Brenner tumor 3 (0.31%) 0 (0.00%) 2 (0.42%) 0 (0.00%) 1 (1.06%)
Sertoli-Leydig tumor 2 (0.21%) 0 (0.00%) 2 (0.42%) 0 (0.00%) 0 (0.00%)
Granulosacell tumor 6 (0.62%) 0 (0.00%) 6 (1.27%) 0 (0.00%) 0 (0.00%)
Histology 0.427 709
Serous 251 (35.4%) 92 (33.3%) 115 (34.3%) 9 (37.5%) 35 (47.3%)
Endometrioid 339 (47.8%) 132 (47.8%) 165 (49.3%) 11 (45.8%) 31 (41.9%)
Mucinous 24 (3.39%) 9 (3.26%) 10 (2.99%) 1 (4.17%) 4 (5.41%)
Clear cell 23 (3.24%) 9 (3.26%) 12 (3.58%) 2 (8.33%) 0 (0.00%)
Neuroendocrine 3 (0.42%) 1 (0.36%) 1 (0.30%) 0 (0.00%) 1 (1.35%)
Mixed/unknown/other 69 (9.73%) 33 (4.65%) 32 (4.51%) 1 (0.14%) 3 (0.42%)
FIGO Stage 0.524 662
I 259 (39.1%) 105 (40.5%) 111 (36.2%) 11 (45.8%) 32 (44.4%)
II 85 (12.8%) 31 (12.0%) 45 (14.7%) 4 (16.7%) 5 (6.94%)
III 242 (36.6%) 95 (36.7%) 110 (35.8%) 7 (29.2%) 30 (41.7%)
IV 76 (11.5%) 28 (10.8%) 41 (13.4%) 2 (8.33%) 5 (6.94%)
Tumour grade 0.510 762
G1 185 (24.3%) 66 (22.2%) 96 (26.2%) 3 (12.5%) 20 (26.7%)
G2 238 (31.2%) 98 (33.0%) 112 (30.6%) 6 (25.0%) 22 (29.3%)
G3 339 (44.5%) 133 (44.8%) 158 (43.2%) 15 (62.5%) 33 (44.0%)
Residual Disease 0.571 441
optimal debulking 303 (68.7%) 118 (67.4%) 144 (70.9%) 10 (76.9%) 31 (62.0%)
(Continued)
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vulvar (VC, p = 0.29) cancer. No significant associations to BG were also found for RFS in peri-
toneal (p = 0.889), tubal (p = 0.814), cervical (p = 0.638), endometrial (p = 0.492) or vaginal
(p = 0.480) cancer. In contrast, associations for RFS and BG were found for OC and VC. No
significant associations for OS were found for the whole cohort (p = 0.287).
Effect of blood group status on RFS and OS in ovarian cancer patients
The OC group comprised 282 patients with a mean age at diagnosis of 60.7 ± 13.7 years and
mean follow-up time of 3.26 ± 4.12 years. BG distribution was 100 (35.5%) with BG O, 138
(48.9%) with A, 10 (3.5%) with AB, and 34 (12.1%) with B. These and additional clinico-patho-
logical data are given in Table 2.
The median time until relapse for OC patients was 25.4 months for BG O, 51.1 months for
A, 50.0 months for AB and 24.0 months for B (Fig 1A and 1B), indicating that patients with
BG A relapsed about two years later than patients with BG O.
Statistical analysis showed a significant (p = 0.039) overall influence of the BG on the time
to relapse in OC (Fig 1C): patients with BG O showed a statistically significant (p = 0.045) 59%
(HR O vs A = 1.59) increased risk for OC relapse and patients with BG B a statistically signifi-
cant (p = 0.036) 82% (HR B vs A = 1.82 = 1/0.55 given in Fig 1C) increased risk for OC relapse
compared to those with BG A, indicating that patients with BG A have better prognosis with a
significant longer relapse-free survival than those with BG O and BG B. The other comparisons
did not reveal any significant differences for relapse risk. Likewise, no difference in OS was
found among the blood groups (p = 0.665). The 5-year OS was 0.694 (95%CI: 0.531–0.907) for
BG O and 0.734 (95%CI: 0.624–0.863) for BG A (values for BG AB and BG B not reported
because of low number of cases and events).
Effect of blood group status on RFS and OS in vulvar cancer patients
The group with VC comprised 67 patients with a mean age at diagnosis of 70.0 ± 13.8 years
and mean follow-up time of 5.15 ± 5.5 years. BG distribution was 35.5% with BG O, 52.2%
with A, 1.5% with AB, and 10.5% with B. The data showed (Fig 2A and 2B) that the median
time until relapse was 305.6 months for BG O (n = 21), 21.4 months for BG B (n = 7), 11.7
months for the one patient with BG AB, and was not estimable for the 28 patients with BG A
(none relapsed within 60 months). Despite the low number of cases and non-estimable data, a
highly significant (p = 0.0024) relationship between the BG and the time to relapse for VC was
Table 1. (Continued)
ABO blood group
ALL O A AB B p n
suboptimal debulking 138 (31.3%) 57 (32.6%) 59 (29.1%) 3 (23.1%) 19 (38.0%)
Survival status 0.962 933
alive 829 (88.9%) 317 (89.0%) 401 (88.5%) 29 (87.9%) 82 (90.1%)
dead of disease 104 (11.1%) 39 (11.0%) 52 (11.5%) 4 (12.1%) 9 (9.89%)
Recurrence 0.009 974
no 750 (77.0%) 298 (79.5%) 368 (78.1%) 24 (70.6%) 60 (63.8%)
yes 108 (23.0%) 77 (20.5%) 103 (21.9%) 10 (29.4%) 34 (36.2%)
Data from gynecological cancer centers (Basel and Zurich, Switzerland) and Sydney (Australia) collected between 1974 and 2014. P-values calculated by t-test or Fisher’s
exact tests.
https://doi.org/10.1371/journal.pone.0195213.t001
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found. Cox regression (Fig 2C) analysis for patients with BG O compared to A showed a trend
for a 4-times longer time to relapse for BG A patients, whereas comparisons among the other
Table 2. Clinico-pathological data of ovarian cancer cohort sorted by blood group.
ABO blood group
ALL O A AB B p n
Characteristic
Number of women 282 100 138 10 34 282
Percentage of total (%) 100 35.46 48.94 3.55 12.06
Cancer Center 0.16 282
Basel 160 (56.7%) 55 (55.0%) 85 (61.6%) 6 (60.0%) 14 (41.2%)
Sydney 87 (30.9%) 36 (36.0%) 33 (23.9%) 3 (30.0%) 15 (44.1%)
Zu¨rich 35 (12.4%) 9 (9.00%) 20 (14.5%) 1 (10.0%) 5 (14.7%)
Mean age (years) (±SD) 60.7 (13.7) 61.1(13.9) 60.2 (13.3) 57.4 (12.3) 63.1 (15.1) 0.599 276
Tumour type 0.397 282
Adenocarcinoma 257 (91.1%) 93 (93.0%) 123 (89.1%) 10 (100%) 31 (91.2%)
Carcinosarcoma (MMMT) 13 (4.61%) 6 (6.00%) 5 (3.62%) 0 (0.00%) 2 (5.88%)
Carcinoid 1 (0.35%) 1 (1.00%) 0 (0.00%) 0 (0.00%) 0 (0.00%)
Brenner tumor 3 (1.06%) 0 (0.00%) 2 (1.45%) 0 (0.00%) 1 (2.94%)
Sertoli-Leydig tumor 2 (0.71%) 0 (0.00%) 2 (1.45%) 0 (0.00%) 0 (0.00%)
Granulosacell tumor 6 (2.13%) 0 (0.00%) 6 (4.35%) 0 (0.00%) 0 (0.00%)
Histology 0.645 261
Serous 160 (61.3%) 53 (56.4%) 83 (65.9%) 4 (40.0%) 20 (64.5%)
Endometrioid 42 (16.1%) 16 (17.0%) 18 (14.3%) 2 (20.0%) 6 (19.4%)
Mucinous 21 (8.05%) 8 (8.51%) 8 (6.35%) 1 (10.0%) 4 (12.9%)
Clear cell 11 (4.21%) 5 (5.32%) 4 (3.17%) 2 (20.0%) 0 (0.00%)
Neuroendocrine 1 (0.38%) 1 (1.06%) 0 (0.00%) 0 (0.00%) 0 (0.00%)
Mixed/unknown/other 26 (9.96%) 11 (11.70%) 13 (10.32%) 1 (10.0%) 1 (3.23%)
FIGO Stage 0.59 247
I 64 (25.9%) 22 (23.9%) 27 (23.7%) 4 (40.0%) 11 (35.5%)
II 21 (8.50%) 10 (10.9%) 8 (7.02%) 1 (10.0%) 2 (6.45%)
III 126 (51.0%) 44 (47.8%) 61 (53.5%) 4 (40.0%) 17 (54.8%)
IV 36 (14.6%) 16 (17.4%) 18 (15.8%) 1 (10.0%) 1 (3.23%)
Tumour grade 0.519 216
G1 34 (15.7%) 14 (17.5%) 14 (13.7%) 1 (12.5%) 5 (19.2%)
G2 35 (16.2%) 17 (21.2%) 12 (11.8%) 1 (12.5%) 5 (19.2%)
G3 147 (68.1%) 49 (61.3%) 76 (74.5%) 6 (75.0%) 16 (61.5%)
Residual Disease 0.783 170
optimal debulking 106 (62.4%) 41 (61.2%) 47 (62.7%) 5 (83.3%) 13 (59.1%)
suboptimal debulking 64 (37.6%) 26 (38.8%) 28 (37.3%) 1 (16.7%) 9 (40.9%)
Survival status 0.781 274
alive 226 (82.5%) 81 (82.7%) 107 (80.5%) 9 (90.0%) 29 (87.9%)
dead of disease 48 (17.5%) 17 (17.3%) 26 (19.5%) 1 (10.0%) 4 (12.1%)
Recurrence 0.128 282
no 174 (61.7%) 67 (67.0%) 86 (62.3%) 6 (60.0%) 15 (44.1%)
yes 108 (38.3%) 33 (33.0%) 52 (37.7%) 4 (40.0%) 19 (55.9%)
Data from gynecological cancer centers (Basel and Zu¨rich, Switzerland) and Sydney (Australia) collected between 1974 and 2014. P-values calculated by T-Tests or
Fisher’s exact Tests.
https://doi.org/10.1371/journal.pone.0195213.t002
Blood groups as prognostic factor for gynecological cancer recurrence
PLOS ONE | https://doi.org/10.1371/journal.pone.0195213 March 29, 2018 6 / 14
groups were obsolete because of respectively low number of cases and non-estimable data.
Data for OS are not reported due to low number of cases and events.
Taken together, the data indicate that BG O is associated with higher risk for disease recur-
rence in OC and VC.
Effect of blood group status on FIGO III ovarian adenocarcinoma
In order to eliminate the contribution of the prognostic effect of the FIGO stage we deter-
mined the RFS and OS in FIGO stage III ovarian adenocarcinoma patients. In this more
homogenous subgroup (n = 108), the median time until relapse was 18.2 months for BG O
(n = 37), 32.2 months for A (n = 53), 18.6 months for AB (n = 4), and 14 months for B
(n = 14), and hence were not significantly different among each other (Fig 3A and 3B). Cox
regression analysis showed a statistically significant two time increased recurrence risk for
FIGO III ovarian carcinoma patients with BG O compared to BG A (HR O vs A = 2.07; 95%
CI: 1.07–4.02; p = 0.0313), while other comparisons did not reveal any significant differences
(Fig 3B). The OS did not differ among the blood groups (p = 0.115). The 5-year OS was 0.714
(95%CI: 0.478–1.000) for BG O and 0.789 (95%CI: 0.619–1.000) for BG A (data for BG AB and
BG B not reported due to low number of cases and events).
Discussion
This retrospective study with various gynecological malignancies showed that relapse-free sur-
vival (RFS) in OC and VC (but not on other gynecological cancers such as peritoneal, cervical,
Fig 1. Time to relapse (A), Kaplan-Meier curve for RFS (B), and HR for disease recurrence (C) in ovarian cancer patients (n = 252). BG O and B patients
showed a significantly increased risk for relapse compared to A patients (59%, p = 0.045 and 82%, p = 0.036, respectively; Cox regression). Hence, BG A patients have
better prognosis with a significant longer RFS than those with O and B. Time to relapse presented as median (months) and 95%CI and compared by overall logrank
test and disease recurrence risk presented as HR and 95%CI. Statistical significance marked by asterisks () or highlighted. NE, not estimable. RFS given as
probability of freedom from relapse as a function of time (months).
https://doi.org/10.1371/journal.pone.0195213.g001
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endometrial, tubal, and endometrial cancers) was significantly influenced the ABO BG status.
Specifically, BG O and B ovarian cancer patients had a considerably increased risk for recur-
rence compared to BG A patients (i.e. BG A patients have a marked better prognosis with a
longer time-to-relapse than BG O and B patients) and BG A vulvar cancer patients at least
tend to have a longer time-to-relapse than patients with BG O. No influence was observed for
DSS and OS for both cancers. Our data indicate that RFS in OC and VC patients is associated
with the ABO blood type, suggesting that the ABO status is an important factor for RFS. The
present study is the first to show the prognostic value of the ABO BG status for RFS, in particu-
lar BG A, in OC and VC and is also the largest data in the English literature addressing the
prognostic value of ABO BG in regards to RFS and DSS in gynecological cancers.
Very little is known from the literature about the relationship between ABO BG and cancer
prognosis (summarized in Table 3). One study on gynecological cancers published (in Italian)
in 1995 [21] reported negative associations between overall survival (OS) and BG A in endo-
metrial and OC when compared to BG O, and a positive association between BG A and OS in
cervical cancer patients. Considering this it seems that OC patients with BG A have a lower
risk for recurrence, no different DSS, but a worse OS than BG O patients, but opposed results
were reported very recently in study with over 700 patients, demonstrating a significantly bet-
ter OS in OC patients with BG A compared to BG O or non-A [22]. In our study, however, no
difference in OS was found in OC patients for any BG.
The largest body of data available however relates to the association of ABO BG with cancer
risk and incidence. The first indication of a possible relationship between BG and cancer risk
Fig 2. Time to relapse (A), Kaplan-Meier curve for RFS (B), and HR for disease recurrence (C) in vulvar cancer patients (n = 57). BG O patients tend to have
increased risk for relapse compared to A patients A (HR O vs A = 4.03, 95%CI: 0.81–20.14, p = 0.089), i.e. A patients have better prognosis with a trend to longer RFS
than patients with BG O. Time to relapse presented as median (months) and 95%CI and compared by overall Logrank Test. Disease recurrence risk presented as HR
and 95%CI by Cox regression (only possible for O vs A owing the small sample size for AB and B). Statistical significance marked by asterisks () or highlighted. NE,
not estimable. RFS given as probability of freedom from relapse as a function of time (months).
https://doi.org/10.1371/journal.pone.0195213.g002
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was published in 1953, reporting a 20% increased incidence of gastric cancer in BG A com-
pared to O [23]. Since then an increasing numbers of often inconsistent data were published,
suggesting that the biological role of ABO antigens may be disease-specific. Patients with BG A
and AB have an increased risk of gallbladder [24], and nasopharyngeal carcinomas [25],
whereas non-O female blood group carriers have been identified with a higher risk of develop-
ing renal cell cancer [26]. BG B has been significantly associated with cardiac and oesophageal
carcinomas [27, 28]. BG O carriers have a reduced risk of developing basal cell carcinoma,
squamous cell carcinoma of the skin [29], and a lower risk of pancreatic cancer [30]. Other
associations have been reported, but the data are not reproducible for lung [31, 32], breast [33,
34] and colorectal cancers [35, 36]. A recent meta-analysis of 89 eligible studies with 100’554
cases from 30 cancer sites calculated a pooled OR for overall cancer risk of 1.12 for A vs non-A
groups and 0.84 for O vs non-O groups [5]. Reports for gynecological cancers are also rare and
mainly suggest increased OC risk for BG A compared to non-A and a decreased risk for BG O
[5–7]. No significant association of blood groups with cervical cancer risk were reported in 8
studies [7] and two studies reported no significant associations in endometrial cancer [7].
Other gynecological cancers are underreported with only two studies without any significant
difference in invasive squamous cell carcinoma of the vulva [37, 38].
All these studies underline the biological role of the BG regarding incidence risk, prognosis,
and outcome in malignant diseases including ovarian, vulvar, and endometrial cancer. Associ-
ations between ABO blood type and modified immune response have been described [39, 40],
but this may not fully explain how the ABO BG are linked to cancer risk incidence. Welshinger
et al. have shown that, although the ovarian surface epithelium usually does not express BG
antigens, ABO antigens were expressed in some areas of activated surface epithelium, in
Fig 3. Time to relapse (A), Kaplan-Meier curve for RFS (B), and HR for disease recurrence (C) in the FIGO III adenocarcinoma patient subgroup (n = 108). BG
O patients have two time increased risk for relapse compared to A patients A, i.e. BG A patients have better prognosis with a significant longer RFS than patients with
O. Time to relapse presented as median (months) and 95%CI and compared by overall Logrank test. Disease recurrence risk presented as HR and 95%CI by Cox
regression. Statistical significance marked by asterisks () or highlighted. NE, not estimable. RFS given as probability of freedom from relapse as a function of time
(months).
https://doi.org/10.1371/journal.pone.0195213.g003
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inclusion cysts and also by one-half of ovarian carcinomas [41], but it is still poorly understood
how BG antigens or altered abundance of BG antigens influence carcinogenesis and whether
BG antigen expression is a consequence of malignant transformation.
It is also poorly understood how BG antigens relate to disease outcome and prognosis. The
expression of BG antigens on cancer cells can be subject to genetic and epigenetic modifica-
tions, e.g. ABO promotor methylation, which in turn might be related to tumor invasion and
Table 3. Studies on the prognostic value of ABO blood group by cancer type.
Author Year n Cancer Blood group Influence on prognostic data Country Publication
negative/positive Survival data
Kaffenberger 2012 900 RCC non-O negative OS USA BJU international 2012;110: E641-6
de Martino 2014 556 RCC no association Austria BJU international 2014;113: E62-6
Lee 2015 3’172 RCC no association Korea J Cancer Res Clin Oncol
Unal 2013 81 NSCLC no association Turkey APJCP 2013;14: 3945–8
Fukumoto 2015 333 NSCLC A, AB negative DFS, OS Japan Journal of epidemiology 2015;25: 110–6.
Yang 2014 496 ESCC non-O positive OS China Int J Clin Exp Med 2014;7: 2214–8
Qin 2015 548 ESCC > subgroup with negativ
NL
non-AB positive OS China OncoTargets and therapy 2015;8: 947–
53
Xu 2016 1’412 Gastric AB positive OS China J Surg Res 2016;201: 188–95.
> subgroup after Gastrectomy A negative OS
Dandona 2010 417 Pancreas no association USA J Natl Cancer Inst 2010;102: 135–7
Ben 2011 1’431 Pancreas no association China Int J Cancer 011;128: 1179–86
316 > subgroup with curative
resection
O positive OS
Rahbari 2012 627 Pancreas O positive OS Germany BMC cancer 2012;12: 319
Cao 2014 1’555 Colon AB positive OS China British journal of cancer 2014;111: 174–
80
Holdsworth 1985 1’001 Breast O positive DFS GB Br Med J 1985;290: 671–3
Costantini 1990 315 Breast O positive OS Italy Oncology 1990;47: 308–12
Klimant 2011 426 Breast no association USA Clinical medicine & research 2011;9:
111–8
Gates 2012 2’036 Breast no association USA Int J Cancer 2012;130: 2129–37
Cihan 2014 335 Breast A, O positive DFS, OS Turkey APJCP 2014;15: 4055–60
Marinaccio 1995 92 Ovary A negative OS Italy Minerva ginecologica 1995;47: 69–76
237 Endometrium A negative OS
639 Cervix no association
Cozzi 2017 713 Ovary positive OS USA PLoS One 2017; 30;12 (5):e0178965
Montavon 2018 282 Ovary A positive RFS Swiss,
AUS
no association OS
56 Peritonum no association
23 Fallopian tube no association
377 Endometrium no association
149 Cervix no association
67 Vulva A positiv RFS
no association OS
11 Vagina no association
RCC (renal cell carcinoma), NSCLC (Non-small Cell Lung Cancer), ESCC (oesophageal squamous cell carcinoma), OS (overall survival), DFS (Disease Free Survival),
RFS (Relapse Free Survival). Current study in italic.
https://doi.org/10.1371/journal.pone.0195213.t003
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metastasis [10]. Certain tumor antigens may mimic the structure of antigens of the ABO sys-
tem. Forssmann antigen, predominantly expressed in stomach and colon tumors, is structur-
ally almost identical to A antigen determinant: BG A carriers may have a diminished tumor
immune response owing the reduced ability in recognizing and attacking tumor cells express-
ing Forssmann antigen[5]. Abundance of A and B antigen in carcinomas derived from tissues
normally not expressing these antigens may promote cancer aggressiveness by increasing cell
motility, resistance to apoptosis, and immune escape [2].
The most important finding of the present study is that OC patients and to some extent vul-
var cancer patients with BG A have substantially longer RFS compared to BG O (and B). This
finding is in line with the recently reported longer survival for OC patients with BG A com-
pared to BG O or non-A [22] and suggests that the lower recurrence risk accounts for this bet-
ter survival. This finding presents a novelty regarding outcome and ABO BG in gynecological
cancers. But open questions remain such as why BG A patients have a better RFS prognosis,
why this advantage is not reflected for DSS, and why no association was found for other gyne-
cological cancers. At least our data suggest that abundance of A antigen (or anti-B antibodies)
delays recurrence or that B antigen (or anti-A antibodies) promotes recurrence in these can-
cers, but it is unknown by which mechanisms these immune molecules influence disease
recurrence. Likewise intriguing is the observed reciprocal relationship between incidence risk
and RFS in OC: women with BG O seem to have a lower incidence, however are more likely to
relapse earlier.
Despite the strong indication of a positive role of BG A on prolonged RFS in OC, we recog-
nizes that the occasionally small sample number (despite an almost 1000 patient mighty
cohort) may limit the value of statistical analysis e.g. for AB patients (least frequent blood
group), rare gynecological cancers (e.g. vulvar, vagina), and small subgroups (e.g. histology,
stage, grade), warranting the conduction of studies with larger cohorts.
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